GlassScriptPhysician profile
Jennifer Wong
NPI 1770085102
$6,938.40
in general payments reported to CMS, 2019-2025
30 companies · $2,041 in 2025
The $2,041 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $615 · 2021: $471 · 2022: $625 · 2023: $1,017 · 2024: $1,500 · 2025: $2,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,304 · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,303.53 |
| Education | $253.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,329.49 | 2019-2025 | Rinvoq |
| Regeneron Healthcare Solutions, INC. | $798.30 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $492.87 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $454.27 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $377.26 | 2024-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $372.66 | 2023-2025 | Zoryve |
| Ucb, INC. | $317.49 | 2022-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $273.27 | 2023-2024 | Vtama |
| Amgen INC. | $269.91 | 2020-2023 | Otezla |
| Pfizer INC. | $269.47 | 2019-2025 | |
| Leo Pharma INC. | $254.19 | 2022-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $249.04 | 2022-2025 | Blu-U |
| Galderma Laboratories, L.P. | $220.77 | 2024-2025 | Nemluvio, Aklief |
| Genentech USA, INC. | $220.33 | 2019-2020 | |
| Genzyme Corporation | $197.29 | 2021-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $164.99 | 2021-2025 | |
| Janssen Biotech, INC. | $159.69 | 2023-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $83.22 | 2022-2024 | |
| Vyne Pharmaceuticals INC. | $74.50 | 2020 | |
| Organon LLC | $63.75 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.29 | 2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.74 | 2022-2023 | Siliq, Targretin |
| Lnhc, INC | $40.94 | 2025 | Zelsuvmi |
| Smith+Nephew, INC. | $28.60 | 2021 | |
| Medtronic, INC. | $28.57 | 2024 | Closurefast |
| Almirall LLC | $26.74 | 2021 | |
| Kyowa Kirin, INC. | $21.93 | 2021 | |
| Bausch Health US, LLC | $18.34 | 2021 | |
| Journey Medical Corporation | $17.81 | 2022 | |
| Mayne Pharma Commercial LLC | $13.68 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.